Cargando…
Timing the Emergence of Resistance to Anti-HIV Drugs with Large Genetic Barriers
New antiretroviral drugs that offer large genetic barriers to resistance, such as the recently approved inhibitors of HIV-1 protease, tipranavir and darunavir, present promising weapons to avert the failure of current therapies for HIV infection. Optimal treatment strategies with the new drugs, howe...
Autores principales: | Arora, Pankhuri, Dixit, Narendra M. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2643484/ https://www.ncbi.nlm.nih.gov/pubmed/19282958 http://dx.doi.org/10.1371/journal.pcbi.1000305 |
Ejemplares similares
-
Emergence of Recombinant Forms of HIV: Dynamics and Scaling
por: Suryavanshi, Gajendra W, et al.
Publicado: (2007) -
Pre-existing resistance in the latent reservoir can compromise VRC01 therapy during chronic HIV-1 infection
por: Saha, Ananya, et al.
Publicado: (2020) -
Broad-spectrum anti-HIV activity and high drug resistance barrier of lipopeptide HIV fusion inhibitor LP-19
por: He, Lin, et al.
Publicado: (2023) -
HIV Genetic Diversity and Drug Resistance
por: Santos, André F., et al.
Publicado: (2010) -
Mutational pathway maps and founder effects define the within-host spectrum of hepatitis C virus mutants resistant to drugs
por: Raja, Rubesh, et al.
Publicado: (2019)